Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer

Bookmark and Share
Published: 19 Dec 2019
Views: 794
Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA

Dr Terry Mamounas speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the ten-year results from the NSABP B-42 trial.

He explains that this study aims to evaluate the effects of aromatase inhibitor therapy with letrozole in patients with postmenopausal, hormone receptor-positive breast cancer, that have completed five years of endocrine therapy.

Dr Mamounas provides an overview of the trial design and reports the findings from this ten-year update - where a trend was observed towards a benefit in disease-free survival.

He also discusses the possible reasons to explain why letrozole did not improve overall survival in this patient population.